Background and Purpose-Ischemic stroke patients with regional very low cerebral blood volume (VLCBV) on baseline imaging have increased risk of parenchymal hemorrhage (PH) after intravenous alteplase-induced reperfusion. We developed a method for automated detection of VLCBV and examined whether patients with reperfused-VLCBV are at increased risk of PH after endovascular reperfusion therapy. Methods-Receiver operating characteristic analysis was performed to optimize a relative CBV threshold associated with PH in patients from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) study. Regional reperfused-VLCBV was defined as regions with low relative CBV on baseline imaging that demonstrated normal perfusion (T max <6 s) on coregistered early follow-up magnetic resonance imaging. The association between VLCBV, regional reperfused-VLCBV and PH was assessed in univariate and multivariate analyses. Results-In 91 patients, the greatest area under the curve for predicting PH occurred at an relative CBV threshold of <0.42
P arenchymal hematoma (PH) is the most feared complication of reperfusion therapy in acute ischemic stroke. Imaging characteristics that are associated with an increased risk of parenchymal hematoma include a large diffusion-weighted imaging (DWI) lesion, 1 a lesion with a severely prolonged T max , 2,3 a very low apparent diffusion coefficient, 4 or a very low cerebral blood volume (VLCBV). 5, 6 Among these variables, VLCBV seems to be the best predictor with high sensitivity and moderate specificity for predicting PH after intravenous thrombolysis. 5, 7 Previous studies investigating the association of VLCBV with PH involved manual processing to obtain VLCBV measurements and were based on data from patients treated with intravenous alteplase (intravenous tissue-type plasminogen activator [tPA]). [5] [6] [7] Here, we evaluate whether patients with VLCBV can be identified with automated image processing software, and whether the presence of VLCBV is associated with the development of parenchymal hemorrhage after endovascular reperfusion.
Methods Patients
The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) study was a prospective observational study of patients who were treated with endovascular therapy. 8 The eligibility criteria for the DEFUSE 2 study were intention to start endovascular stroke therapy within 12 hours of symptom onset, age ≥18 years, baseline National Institute of Health Stroke Scale (NIHSS) ≥5,
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May 2015 nonpregnant state, premorbid modified Ranking Scale (mRS) ≤2, and no contraindication for magnetic resonance imaging (MRI).
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Imaging Protocol and Analysis
A standardized imaging protocol using 1.5 or 3 Tesla MRI systems was used. Patients received 3 scans, such as a baseline MR scan (gradient recalled echo, intracranial magnetic resonance angiogram, diffusion and perfusion sequence obtained within 90 minutes before the start of the endovascular procedure), an early follow-up scan (same sequences as baseline) within 12 hours after the endovascular procedure, and a late follow-up scan (gradient recalled echo, diffusion, and fluid-attenuated inversion recovery) on day 5 or at discharge from the hospital, whichever came sooner. 8 Additional imaging was obtained as clinically indicated. Relative cerebral blood volume (rCBV) maps were generated using fully automated image processing software (Rapid Processing of Perfusion and Diffusion [RAPID]). 9 Relative CBV values were calculated for each pixel by dividing its CBV by a smoothed CBV of its mirror pixel in the contralateral hemisphere. For each patient, the rCBV lesion volume was calculated for each rCBV threshold ranging between 0 and 1 in 0.01 increments. Assessment of rCBV lesions was restricted to brain territory with abnormal perfusion (T max >6 s) to reduce artifact. 7 The rCBV ratio threshold and the rCBV lesion volume threshold that were associated with the best prediction of PH were determined with receiver operator curve analyses and used to define patients who had very low CBV (VLCBV). More specifically, optimal VLCBV criteria were defined by first establishing the rCBV ratio threshold with the largest area under the receiver operating characteristic and next, the rCBV lesion volume, at this rCBV ratio threshold, with the highest Youden index.
Regional reperfusion of the VLCBV lesion was assessed by 2 investigators on the coregistered subacute MR perfusion scan, obtained 12 hours after endovascular therapy. It was defined as restoration of perfusion (T max <6 s) of the baseline VLCBV lesion. Patients with regional reperfusion of their VLCBV lesion were categorized as regional reperfused-VLCBV. Reperfusion was also assessed globally by an experienced neuroendovascular radiologist (M.P.M.) on the digital subtraction angiography. Patients with VLCBV and a modified Thrombolysis in Cerebral Infarction score of 2b to 3 were considered to have global reperfused-VLCBV. 10 Collateral status was rated on the digital subtraction angiography images by the same investigator according a previously defined 5-point system where 0 is no collateral flow and 4 is complete and rapid collateral flow to the ischemic territory. 11 Target mismatch pattern on baseline MRI was defined per criteria used in the parent study. 8 The presence of PH (either PH1 or PH2) was assessed on the gradient recalled echo sequence of the subacute MRI.
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Statistical Analysis
Univariate analyses were used to assess the association of clinical and radiological variables with 2 outcome variables, such as VLCBV and PH. Independent predictors of PH were assessed with multivariate analyses. Variables that were significant at an α=0.1 in the univariate analyses were entered in a multivariate logistic regression model. A backward elimination procedure was used, in which variables with an α>0.05 were eliminated from the model. Separate multivariate models were constructed for VLCBV and reperfused-VLCBV, to avoid the simultaneous inclusion of predictor variables that are closely correlated. For other predictors that are correlated (eg, NIHSS and DWI lesion volume), only the predictor that had the strongest association with PH was included in the multivariate model. Differences in distributions of continuous variables were assessed with the Mann-Witney U test. For the distribution of the mRS, categories 5 and 6 were collapsed into 1 category. Analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC) and StatsDirect (United Kingdom).
Results
The DEFUSE 2 study reported findings on 99 patients. 8 Of these, 91 patients had adequate baseline and subacute MRI data for assessment of VLCBV, regional reperfusion, and PH. These 91 patients were included in this analysis ( Figure 1 ). The optimal rCBV lesion criteria on baseline MRI to predict PH were an rCBV ratio <0.42 (area under the curve, 0.768) and a volume ≥3.55 mL (Youden index, 0.578). These criteria were implemented in automated perfusion processing software. VLCBV was present on the baseline MRI in 48% (n=44) of the patients. Compared with patients without VLCBV, patients with VLCBV had larger DWI lesions and higher baseline NIHSS scores, whereas collateral rating and age did not differ between groups (Table 1) . Among patients with VLCBV, 82% (36 of 44) had regional reperfusion on follow-up PWI and 43% (19 of 44) had global reperfusion (Thrombolysis in Cerebral Infarction score, 2b or 3). Parenchymal hematoma occurred in 39% (17 of 44) of patients with VLCBV compared with 2% (1 of 47) of patients without VLCBV (P<0.0001; Figure 1 ). The test characteristics of VLCBV for predicting PH in the overall cohort and separately in patients with and without the target mismatch are listed in Table 2 . This table also reports the hemorrhage rates and test characteristics of VLCBV in the setting of regional and global reperfusion.
Significant baseline predictors of PH in univariate analyses were the NIHSS score, DWI lesion volume, bridging with intravenous tPA, and the presence of VLCBV or regional reperfused-VLCBV (Table 3) . In multivariate analysis, VLCBV remained as an independent predictor of PH (odds ratio In this multivariate model, bridging with intravenous tPA was removed in the backward elimination procedure because the association between this variable and PH was borderline significant (OR, 3.7; 95% CI, 0.97-14.1; P=0.056).
VLCBV was a predictor of poor functional outcome (mRS>2) at 90 days (OR, 2.7; 95% CI, 1.1-6.2). After adjusting for age and baseline NIHSS the OR for poor functional outcome was 2.9 (95% CI, 1-8.5; P=0.05). VLCBV was also associated with a shift in the distribution of mRS toward worse functional outcome (P=0.047).
Discussion
Our results demonstrate that VLCBV is a strong predictor of parenchymal hematoma in patients undergoing endovascular treatment for acute stroke, particularly in the setting of regional reperfusion. The optimal definition for VLCBV was an rCBV lesion of at least 3.55 mL at an rCBV threshold of <0.42. VLCBV defined with these criteria had excellent negative predictive value and moderate positive predictive value for predicting PH, both in patients with and without the target mismatch pattern. Given those test characteristics, the absence Regional reperfused-VLCBV includes patients with VLCBV who have reperfusion of their VLCBV lesion on follow-up PWI. Global reperfused-VLCBV includes patients with VLCBV who have Thrombolysis in Cerebral Infarction 2B-3 scores on their angiogram at completion of the endovascular procedure. NPV indicates negative predictive value; PH, parenchymal hematoma; PPV, positive predictive value; TMM, target mismatch; and VLCBV, very low cerebral blood volume. Poor collateral flow is defined as a score of 0-2 on a 5-point collateral scale. DWI indicates diffusion-weighted imaging; IQR, international quartile range; IV, intravenous; mRS, modified Ranking Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; and VLCBV, very low cerebral blood volume.
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of VLCBV can be used to reassure physicians and patients of a very low risk of PH after endovascular treatment.
For an imaging characteristic, such as VLCBV, to be used for risk stratification, it is important to be able to assess its presence in a reliable, reproducible, and consistent manner. Automated image analysis programs can be useful in this regard. 15 We integrated the VLCBV algorithm within an existing fully automated postprocessing software suite for perfusion imaging (RAPID). This program generated easy to interpret VLCBV maps (Figure 2 ) within 5 minutes of processing time, which permits its use for real-time risk stratification. 9 Our methodology for defining VLCBV differs some from previous studies. Specifically, our methodology is based on a very low CBV relative to a mirrored region in the contralateral hemisphere, whereas previous studies used the entire contralateral hemisphere as the reference region. Nevertheless, the results of this study are in line with those of previous studies, which also report excellent sensitivity/negative predictive value and moderate to good specificity/positive predictive value for predicting PH based on VLCBV. [5] [6] [7] 16 Our finding that specificity is improved in the presence of regional reperfusion of the VLCBV lesion is also in accordance with previous studies. 7 In our study, patients with VLCBV developed PH exclusively in the setting of regional reperfusion (Figure 1) . In addition to regional reperfusion, we evaluated the effect of global reperfusion (ie, reperfusion rated according to postprocedural modified Thrombolysis in Cerebral Infarction scores) on the association between VLCBV and PH. In the presence of global reperfusion, specificity for predicting PH increased but because of poor spatial agreement between the region of reperfusion and the VLCBV lesion, sensitivity was dramatically reduced (94%-50%). Taken together with the results of the previous studies, our results indicate that VLCBV is a predictor of PH in the setting of regional reperfusion, regardless of whether reperfusion is achieved through intravenous thrombolysis or endovascular therapy.
In addition to VLCBV, bridging with intravenous tPA was an independent predictor of PH after endovascular therapy in our study. This association could not be evaluated in previous VLCBV studies because these studies were limited to patients treated with intravenous tPA alone. 5, 7 The association between bridging with intravenous tPA and PH was slightly weaker in the multivariate model with reperfused-VLCBV compared with the model with VLCBV, suggesting that the effect of tPA may, in part, be mediated by tPA-induced reperfusion. However, even after adjusting for reperfused-VLCBV, our results show a trend toward an independent association between bridging with intravenous tPA and PH (P=0.06). This is a novel finding, which suggests that bridging with intravenous tPA may increase the risk of PH after endovascular reperfusion. These findings should, however, strictly be viewed as hypothesis generating and require validation in other data sets as they are in contrast with previous studies, which have not shown an association between bridging with intravenous tPA and PH or SICH after endovascular therapy. [17] [18] [19] [20] The VLCBV criteria defined in this study and the test characteristics of VLCBV for predicting PH will also need to be validated. A larger data set is necessary to confirm that VLCBV improves the risk stratification compared with the sole use of a DWI lesion volume threshold. Given the increasing use of computed tomographic perfusion before endovascular therapy, future studies should further elucidate whether an analogous approach using computed tomographic perfusion can equal the performance of VLCBV based on MR perfusion. Data suggest that imaging prediction of hemorrhage using computed tomographic perfusion may require slightly different parameters. 2 If the results of this study are validated, VLCBV can be used for risk stratification of patients scheduled to undergo endovascular therapy in trials and routine clinical practice. Although the modest positive predictive value precludes its use as a criterion to exclude patients from endovascular therapy, its excellent sensitivity and negative predictive value can reassure physicians and patients of the relative safety of endovascular treatment in the absence of VLCBV. 
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